SourcingLink.net to Investigate the Potential of Combining its Novel Autologous Immune-Therapy with Synergistic Oncology Ther...
February 12 2019 - 4:13PM
InvestorsHub NewsWire
San Francisco, CA -- February 12, 2019 -- InvestorsHub NewsWire
-- SourcingLink.net (OTC PINK: SNET), based in San Francisco,
is a pioneering biotech company focused on oncology
. The company is developing its
proprietary autologous immune-therapy approach in
oncology. SNET envisions developing its strategic goals
for the most effective therapies with a durable response and
minimum adverse effects. The
company believes that its autologous immune-therapy as a
monotherapy and/or when combined with other therapies such as
chemos, Immune Check Point Inhibitors, radiation and /or
immuno-therapies will be a "game changer".
The National Cancer Institute in 2018 estimated 1,736,350 new
cases of cancer in the US and 609,640 people died as a result of
cancer. According to a 2018 report by WHO, cancer is the
second leading cause of death in the world. Cancer, according
to the report was responsible for an estimated 9.6 million deaths
in 2018. The global growth in oncology drug market according
to the IMS is expected to be between 7.5-10.5% through 2020 and the
market is projected to reach $150 billion. Subject to
regulatory approval, SourcingLink.net expects to capture the market
share through commercialization of its products and/or
through strategic partnerships with the big pharmas.
SourcingLink.net has licensed and strategically partnered
with pioneering biotech and pharmaceutical companies in
the rapidly emerging field of oncology for achieving its mission,
goals and vision.
About SourcingLink.net:
SourcingLink.net, Inc. ("SNET") is a pioneering oncology
company dedicated to developing , manufacturing and
commercialization of therapeutics. SNET licensed Tulynode's patent
pending Autologous Immuno-therapy for durable therapy response
using an extracorporeal device.
SourcingLink.net prides itself for having a world-class
Advisory Board that keeps the Company leadership in the forefront
of developing technologies in cancer research, biotechnology
and healthcare. SourcingLink.net is currently engaging in
research and development of therapeutics for oncology.
SourcingLink.net is committed to its core corporate mission
and values of highest U.S. Pharma Code of Conduct standards of
behavior for being in compliance with the laws, regulations,
company directives and guidance.
Forward-looking Statements:
This release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements, which contain words such as
“expect”, “believe” or “plan”, by their nature address matters that
are, to different degrees, uncertain. These uncertainties may
cause actual future events to be materially different than those
expressed in our forward-looking statements. We do not
undertake to update our forward-looking statements.
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
email: info@sourcinglink.net
website: www.sourcinglink.net
Source: SourcingLink.net, Inc.